-
Capital, M&A & Industry Strategy3 weeks agoMatchpoint’s $150M tops the week’s private rounds: Venture Report
BIOCENTURY | FINANCEMATCHPOINT’S $150M TOPS THE WEEK’S PRIVATE ROUNDS: VENTURE REPORTForbion raises €2.3 billion in new funds
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoMFN model is an elephant in a mousehole, PhRMA says
BIOCENTURY | POLITICS, POLICY & LAWMFN MODEL IS AN ELEPHANT IN A MOUSEHOLE, PHRMA SAYSLawsuit challenges legality of GLOBE and similar reference-pricing Medicare models
-
Synthetic Biology, Genomics & Advanced Therapeutics3 weeks agoCaribou abandons allogeneic CAR Ts: Is the allo era ending? A perspective
BIOCENTURY | EDITOR'S COMMENTARYCARIBOU ABANDONS ALLOGENEIC CAR TS: IS THE ALLO ERA ENDING? A PERSPECTIVEThe exit of another pioneer underscores a shrinking opportunity as T cell...
-
Drug Discovery & Therapeutics4 weeks agoInvasive fungal infections: a pipeline finally branching beyond the cell wall
BIOCENTURY | PRODUCT DEVELOPMENTINVASIVE FUNGAL INFECTIONS: A PIPELINE FINALLY BRANCHING BEYOND THE CELL WALLMapping the mechanisms of nine clinical-stage antifungal programs to pathogen coverage
-
Capital, M&A & Industry Strategy4 weeks agoLayoffs at Caribou as two CAR Ts scrapped
BIOCENTURY | MANAGEMENT TRACKSLAYOFFS AT CARIBOU AS TWO CAR TS SCRAPPEDPlus: David Liu joining Vir as CMO — and more
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoTCG X set to invest $600M from dedicated Asia fund
BIOCENTURY | FINANCETCG X SET TO INVEST $600M FROM DEDICATED ASIA FUND‘Full circle’ moment for the firm’s Chen Yu
-
Drug Discovery & Therapeutics4 weeks agoCNS oligo delivery – the next frontier for brain shuttles
BIOCENTURY | DISCOVERY & TRANSLATIONCNS OLIGO DELIVERY – THE NEXT FRONTIER FOR BRAIN SHUTTLESPreclinical studies are revealing the design rules for systemic delivery to the brain...
-
Capital, M&A & Industry Strategy4 weeks agoRougeTx: Reattaching pericytes to stabilize vessels in HHT
BIOCENTURY | EMERGING COMPANY PROFILEROUGETX: REATTACHING PERICYTES TO STABILIZE VESSELS IN HHTLeiden University Medical Center spinout raises $58M series A to take an oral small molecule into...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoChina deals, Beam lawsuit, MFN models, Nobel winners — a BioCentury podcast
BIOCENTURY | DEALSCHINA DEALS, BEAM LAWSUIT, MFN MODELS, NOBEL WINNERS — A BIOCENTURY PODCASTPharma partnering in China gets earlier and broader
-
Regulatory Intelligence & Drug Approvals4 weeks agoNobel Prize for optogenetics arrives as first therapy nears FDA decision
BIOCENTURY | DISCOVERY & TRANSLATIONNOBEL PRIZE FOR OPTOGENETICS ARRIVES AS FIRST THERAPY NEARS FDA DECISIONNanoscope leads direct therapeutic applications, while MapLight uses the technology to guide...
Widespread atropine use fails to sway FDA advisors on Sydnexis data
At least 11 PDUFAs on FDA’s November docket
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
